

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1509)

**(1) QUARTERLY UPDATE ANNOUNCEMENT
ON THE RESUMPTION PROGRESS;
(2) DELAY IN PUBLICATION OF 2020 INTERIM RESULTS;
(3) DELAY IN DESPATCH OF THE ANNUAL REPORTS FOR
THE YEARS ENDED 31 DECEMBER 2018 AND 2019 AND
THE INTERIM REPORTS FOR THE SIX MONTHS
ENDED 30 JUNE 2019 AND 30 JUNE 2020;
AND
(4) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Harmonicare Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.24A of the Listing Rules.

Reference is made to (1) the announcement of the Company dated 28 March 2019 in relation to its delay in the publication of the 2018 Annual Results and despatch of the 2018 Annual Report, (2) the announcement of the Company dated 7 May 2019 in relation to its publication of unaudited management accounts for the year ended 31 December 2018 and the engagement of its Internal Control Consultant, (3) the announcement of the Company dated 12 June 2019 in relation to the guidance received from the Stock Exchange regarding the resumption of trading of the Company’s shares on the Stock Exchange, (4) the quarterly update announcement of the Company dated 28 June 2019 in relation to, among others, its resumption progress, (5) the update announcement of the Company dated 31 July 2019 in relation to the progress of its internal control review, (6) the announcement of the Company dated 30 August 2019 in relation to, among others, further delay in publication of the 2018 Annual Results and the delay in publication of the 2019 Interim Results, (7) the quarterly update announcement of the Company dated 29 September 2019 in relation to, among others, its resumption progress, (8) the quarterly update announcement of the Company dated 24 December 2019, (9) the voluntary announcement of the Company dated 10 March 2020 on the impact of novel coronavirus (COVID-19) epidemic on the Group’s business operations, (10) the supplemental announcement of the Company dated 25 March 2020 on the results of its internal control review, (11) the quarterly update announcement of the Company dated 31 March 2020 in relation to, among others, its resumption progress, (12) the announcement of the Company dated 15 June 2020 in relation to, among others, the cessation of construction of a subsidiary, (13) the quarterly update announcement of the Company dated 30 June 2020 in relation to, among others, its resumption progress (the “**Quarterly Update Announcement**”) and (14) the update announcement of the Company dated 17 July 2020 in relation to the progress of its internal control review (the “**Comprehensive IC Review Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Quarterly Update Announcement unless otherwise stated herein.

BUSINESS OPERATION

The Group is mainly engaged in providing high-quality healthcare services to women and children. The Group has continued its normal business operations since the suspension of trading in the Company's shares. Save as disclosed in the previous quarterly update announcements of the Company, since 1 April 2019 and up to the date of this announcement, there has been no major change on the business operations of the Group.

PROGRESS OF INTERNAL CONTROL REVIEW

As disclosed in the Comprehensive IC Review Announcement, on 17 July 2020, the Company appointed Netis Advisory Limited as its internal control consultant to conduct a comprehensive review of the Group's internal control procedures (the "**Review**") which will cover all of the Group's significant subsidiaries and to the extent practicable, its major associated companies, for the period between 1 January 2018 and 31 July 2020 in order to comprehensively evaluate the Group's internal control systems.

A latest draft report on the Review (the "**Report**") and the plan for measures to rectify the internal control deficiencies identified in the draft Report (the "**Plan**") were sent to the Company on 21 September 2020. The Company is currently responding to the findings in the Report and implementing necessary changes as recommended therein.

The Company will make announcement(s) on further updates on the progress, if applicable, and the findings of the Review in compliance with the Listing Rules as and when appropriate.

DELAY IN PUBLICATION OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 AND DELAY IN DESPATCH OF THE INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2020

Under Rule 13.49(6) of the Listing Rules, the Company was required to publish the announcement in relation to its preliminary results for the six months ended 30 June 2020 (the "**2020 Interim Results**") on a date not later than two months after the end of that period of six months, i.e. on or before 31 August 2020. Given that the Company has still not been able to finalize and publish its 2018 and 2019 Annual Results, the Board was not able to finalize the 2020 Interim Results on or before 31 August 2020 as required. The Board acknowledges that the delay in the publication of the 2020 Interim Results constituted non-compliance with Rule 13.49(6) of the Listing Rules. Accordingly, the despatch of the Company's interim report for the six months ended 30 June 2020 (the "**2020 Interim Report**") was not ready by 30 September 2020 as required under the Listing Rules.

The Company will publish further announcement(s) to inform Shareholders and potential investors of the Company of any material developments in connection with the 2018 and 2019 Annual Results and the 2019 and 2020 Interim Results as and when appropriate.

UPDATE ON THE TIMELINE IN FULFILLING THE RESUMPTION CONDITIONS

As disclosed in the Quarterly Update Announcement, the Company is in progress of cooperating with ZHONGHUI ANDA CPA Limited to solve the outstanding matters previously identified by Deloitte. Further, due to travel and work restrictions in connection with the Epidemic, the reporting and audit processes of the Group's outstanding financial statements are significantly affected. As a result, the Company expects further delay in the publication of its outstanding financial results and despatch of its outstanding financial reports.

The following table sets forth the pending events and update in the expected timetable for resumption of trading in the shares of the Company:

Key event	Timetable
Publication of the 2018 Annual Results	Subject to further assessment by the Board
Publication of the 2018 Annual Report	Subject to further assessment by the Board
Publication of the 2019 Interim Results	Subject to further assessment by the Board
Publication of the 2019 Interim Report	Subject to further assessment by the Board
Publication of the 2019 Annual Results	Subject to further assessment by the Board
Publication of the 2019 Annual Report	Subject to further assessment by the Board
Publication of the 2020 Interim Results	Subject to further assessment by the Board
Publication of the 2020 Interim Report	Subject to further assessment by the Board
Resumption of trading in the shares of the Company	Subject to further assessment by the Board

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2019. Trading in the Shares will remain suspended until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Harmonicare Medical Holdings Limited
Lin Yuming
Chairman, Executive Director and President

Hong Kong, 30 September 2020

As at the date of this announcement, the executive directors of the Company are Mr. Lin Yuming, Mr. Yang Guo and Mr. Wei Rongda; the non-executive directors of the Company are Mr. Lin Yuguo, Mr. Qiu Jianwei and Mr. Xu Jun; and the independent non-executive directors of the Company are Ms. Fang Lan, Mr. Cai Jiangnan and Ms. Hsu Wai Man Helen.